NKTR – Nektar Therapeutics

Nektar Therapeutics

NKTR

$0.71

Name : Nektar Therapeutics

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $132,133,840.00

EPSttm : -0.63

Nektar Therapeutics

$0.71

0.67%

$0.0048

Float Short %

4.98

Margin Of Safety %

Put/Call OI Ratio

0.06

EPS Next Q Diff

EPS Last/This Y

-0.14

EPS This/Next Y

-0.05

Price

0.71

Target Price

4.92

Analyst Recom

1.75

Performance Q

7.06

Relative Volume

1.3

Beta

0.57

Ticker: NKTR

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	NKTR	0.6037	0.05	0.22	43396
2025-04-15	NKTR	0.6376	0.06	0.01	43598
2025-04-16	NKTR	0.6063	0.05	0.00	44142
2025-04-17	NKTR	0.6419	0.05	0.00	44807
2025-04-18	NKTR	0.6364	0.05	0.00	44807
2025-04-21	NKTR	0.6291	0.05	0.18	44026
2025-04-22	NKTR	0.6651	0.05	0.35	44143
2025-04-23	NKTR	0.6859	0.06	0.36	44804
2025-04-24	NKTR	0.7332	0.06	0.19	44929
2025-04-25	NKTR	0.7751	0.06677877084677	0.0084317032040472	46311
2025-04-28	NKTR	0.7558	0.064063734527258	0.0008405716	48483
2025-04-29	NKTR	0.7407	0.06	0.00	50084
2025-04-30	NKTR	0.788	0.06	0.00	50392
2025-05-01	NKTR	0.7784	0.06	0.00	50357
2025-05-02	NKTR	0.7521	0.06	0.06	51008
2025-05-05	NKTR	0.6862	0.06	0.01	50869
2025-05-06	NKTR	0.6466	0.06	0.34	50878
2025-05-07	NKTR	0.6057	0.06	0.07	51248
2025-05-08	NKTR	0.6128	0.06	0.02	51529
2025-05-09	NKTR	0.5919	0.06	0.19	51847
2025-05-12	NKTR	0.7143	0.06	0.00	51729
2025-05-13	NKTR	0.7	0.06	0.00	54178
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	NKTR	0.60	1.3	-	-0.72
2025-04-15	NKTR	0.64	1.3	-	-0.72
2025-04-16	NKTR	0.61	1.3	-	-0.72
2025-04-17	NKTR	0.64	1.3	-	-0.72
2025-04-18	NKTR	0.64	1.3	-	-0.72
2025-04-21	NKTR	0.63	1.3	-	-0.72
2025-04-22	NKTR	0.66	1.3	-	-0.72
2025-04-23	NKTR	0.69	1.3	-	-0.72
2025-04-24	NKTR	0.74	1.3	-	-0.72
2025-04-25	NKTR	0.78	1.3	-	-0.72
2025-04-28	NKTR	0.76	1.3	-	-0.72
2025-04-29	NKTR	0.74	1.3	-	-0.72
2025-04-30	NKTR	0.80	1.3	-	-0.72
2025-05-01	NKTR	0.78	1.3	-	-0.72
2025-05-02	NKTR	0.75	1.3	-	-0.72
2025-05-05	NKTR	0.69	1.3	-	-0.72
2025-05-06	NKTR	0.65	1.3	-	-0.72
2025-05-07	NKTR	0.61	1.3	-	-0.72
2025-05-08	NKTR	0.62	1.3	-	-0.72
2025-05-09	NKTR	0.59	1.3	-	-0.72
2025-05-12	NKTR	0.71	1.3	-	-0.72
2025-05-13	NKTR	0.71	-2.3	-	-0.72
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	NKTR	-4.38	-5.94	4.33
2025-04-15	NKTR	-4.38	-5.94	4.33
2025-04-16	NKTR	-4.38	-5.94	4.33
2025-04-17	NKTR	-4.38	-5.94	4.33
2025-04-18	NKTR	-4.38	-5.94	4.33
2025-04-21	NKTR	-4.38	-6.03	4.33
2025-04-22	NKTR	-4.38	-6.03	4.33
2025-04-23	NKTR	-4.38	-6.03	4.33
2025-04-24	NKTR	-4.38	-6.03	4.33
2025-04-25	NKTR	-4.38	-6.03	4.33
2025-04-28	NKTR	-4.38	-8.71	4.54
2025-04-29	NKTR	-4.38	-8.71	4.54
2025-04-30	NKTR	-4.38	-8.71	4.54
2025-05-01	NKTR	-4.38	-8.71	4.54
2025-05-02	NKTR	-4.38	-8.71	4.54
2025-05-05	NKTR	-4.38	-8.02	4.54
2025-05-06	NKTR	-4.38	-8.02	4.54
2025-05-07	NKTR	-4.38	-8.02	4.54
2025-05-08	NKTR	-4.38	-8.02	4.54
2025-05-09	NKTR	-4.38	-8.02	4.54
2025-05-12	NKTR	-4.38	-6.55	4.98
2025-05-13	NKTR	-4.38	-6.55	4.98
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.18

Avg. EPS Est. Next Quarter

-0.18

Insider Transactions

-4.38

Institutional Transactions

-6.55

Beta

0.57

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.4

Max Drawdown 5-Year %

-98.3

Target Price

4.92

P/E

Forward P/E

PEG

P/S

1.51

P/B

9.62

P/Free Cash Flow

EPS

-0.64

Average EPS Est. Cur. Y

-0.72

EPS Next Y. (Est.)

-0.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-152.49

Relative Volume

1.3

Return on Equity vs Sector %

-219.5

Return on Equity vs Industry %

-202.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Nektar Therapeutics

Sector: Healthcare

Industry: Biotechnology

Employees: 61

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

stock quote shares NKTR – Nektar Therapeutics Stock Price stock today

news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025

marketwatch NKTR – Nektar Therapeutics yahoo finance google finance

stock history NKTR – Nektar Therapeutics invest stock market

stock prices NKTR premarket after hours

ticker NKTR fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

NKTR – Nektar Therapeutics

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NKTR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y